Tremelimumab
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Product Specifications
CAS Number
745013-59-6
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1135750-01 0.02 mg (E-Coli)
Recombinant Mycobacterium sp. Pantothenate kinase (coaA)
Ask
View Details MBS1135750-02 0.02 mg (Yeast)
Recombinant Mycobacterium sp. Pantothenate kinase (coaA)
Ask
View Details MBS1135750-03 0.1 mg (E-Coli)
Recombinant Mycobacterium sp. Pantothenate kinase (coaA)
Ask
View Details MBS1135750-04 0.1 mg (Yeast)
Recombinant Mycobacterium sp. Pantothenate kinase (coaA)
Ask
View Details